前列腺癌双极雄激素治疗的研究进展  

Advances in the treatment of prostate cancer with bipolar androgen therapy

作　　者：尤祥云 孙德明[1] 喻俊峰[1] 易成[1] 向振东 YOU Xiangyun;SUN Deming;YU Junfeng;YI Cheng;XIANG Zhendong(Department of Urology,People′s Hospital of China Three Gorges University,First People′s Hospital of Yichang,Yichang,Hubei,443000,China)

机构地区：[1]三峡大学人民医院宜昌市第一人民医院泌尿外科,湖北宜昌443000

出　　处：《临床泌尿外科杂志》2021年第12期989-992,共4页Journal of Clinical Urology

基　　金：湖北省自然科学基金面上类项目(No:2020CFB379);三峡大学学位论文培优基金项目(No:2020SSPY108);宜昌市财政科技专项基金(No:A20-2-021)。

摘　　要：双极雄激素治疗(bipolar androgen therapy, BAT)是去势抵抗性前列腺癌(castration resistant prostate cancer, CRPC)的新疗法,可显著降低部分患者血清前列腺癌特异性抗原(prostate specific antigen, PSA)水平、提高患者生活质量和恢复去势治疗的敏感性,在CRPC患者的治疗中展现了巨大潜力,本文对BAT在前列腺癌中的相关研究进展作一综述。Bipolar androgen therapy(BAT) is a novel treatment for castration resistant prostate cancer(CRPC), which can significantly reduce the level of prostate specific antigen in serum and improve the quality of life for patients. Now, there are significant advantages in the treatment of CRPC with BAT, so this article reviews the progress of clinical researchs of BAT in prostate cancer.

关 键 词：双极雄激素治疗 去势抵抗性前列腺癌 前列腺癌特异性抗原 雄激素受体 

分 类 号：R737.25[医药卫生—肿瘤]